Comparative In Vitro and In Silico Analyses of Variants in Splicing Regions of BRCA1 and BRCA2 Genes and Characterization of Novel Pathogenic Mutations

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Colombo, Mara ^a   de Vecchi, Giovanna ^a   Caleca, Laura ^a   Foglia, Claudia ^a   Ripamonti, Carla B ^a   Ficarazzi, Filomena ^b,c   Barile, Monica ^d   Varesco, Liliana ^e   Peissel, Bernard ^a   Manoukian, Siranoush ^a   Radice, Paolo ^a,c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b IFOM IEO Campus   (Italy)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; MESSENGER RNA; SINGLE STRANDED DNA;

ARTICLE; BIOINFORMATICS; CODON; COMPUTER ANALYSIS; COMPUTER MODEL; CONTROLLED STUDY; DNA BINDING; DNA SEQUENCE; GENE DELETION; GENE INTERACTION; GENE MUTATION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MATHEMATICAL COMPUTING; RNA SPLICING; TUMOR SUPPRESSOR GENE; UPREGULATION; WILD TYPE;

CELL LINE, TRANSFORMED; GENES, BRCA1; GENES, BRCA2; HUMANS; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA SPLICING; RNA, MESSENGER;

EID: 84874299712     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057173     Document Type: Article

References (59)

1. Stratton MR, Rahman N, (2008) The emerging landscape of breast cancer susceptibility. Nat Genet 40: 17-22.
2. Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M, (2010) Genetic susceptibility to breast cancer. Mol Oncol 4: 174-91.
3. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, et al. (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72: 1117-30.
4. Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, Lenoir GM, Mazoyer S, (2002) The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. Hum Mol Genet 11: 2805-14.
5. Spurdle AB, (2010) Clinical relevance of rare germline sequence variants in cancer genes: evolution and application of classification models. Curr Opin Genet Dev 20: 315-23.
6. Lindor NM, Guidugli L, Wang X, Vallee MP, Monteiro AN, et al. (2012) A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). Hum Mutat 33: 8-21.
7. Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, et al. (2007) A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 81: 873-83.
8. Campos B, Diez O, Domenech M, Baena M, Balmana J, et al. (2003) RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain. Hum Mutat 22: 337.
9. Claes K, Poppe B, Machackova E, Coene I, Foretova L, et al. (2003) Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2. Genes Chromosomes Cancer 37: 314-20.
10. Tesoriero AA, Wong EM, Jenkins MA, Hopper JL, Brown MA, et al. (2005) Molecular characterization and cancer risk associated with BRCA1 and BRCA2 splice site variants identified in multiple-case breast cancer families. Hum Mutat 26: 495.
11. Bonatti F, Pepe C, Tancredi M, Lombardi G, Aretini P, et al. (2006) RNA-based analysis of BRCA1 and BRCA2 gene alterations. Cancer Genet Cytogenet 170: 93-101.
12. Chen X, Truong TT, Weaver J, Bove BA, Cattie K, et al. (2006) Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression. Hum Mutat 27: 427-35.
13. Bonnet C, Krieger S, Vezain M, Rousselin A, Tournier I, et al. (2008) Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene. J Med Genet 45: 438-46.
14. Vreeswijk MP, Kraan JN, van der Klift HM, Vink GR, Cornelisse CJ, et al. (2009) Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs. Hum Mutat 30: 107-14.
15. Sanz DJ, Acedo A, Infante M, Duran M, Perez-Cabornero L, et al. (2010) A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients. Clin Cancer Res 16: 1957-67.
16. Thery JC, Krieger S, Gaildrat P, Revillion F, Buisine MP, et al. (2011) Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes. Eur J Hum Genet 19: 1052-8.
17. Whiley PJ, Guidugli L, Walker LC, Healey S, Thompson BA, et al. (2011) Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary. Hum Mutat 32: 678-87.
18. Acedo A, Sanz DJ, Duran M, Infante M, Perez-Cabornero L, et al. (2012) Comprehensive splicing functional analysis of DNA variants of the BRCA2 gene by hybrid minigenes. Breast Cancer Res 14: R87.
19. Gaildrat P, Krieger S, Di GD, Abdat J, Revillion F, et al. (2012) Multiple sequence variants of BRCA2 exon 7 alter splicing regulation. J Med Genet 49: 609-17.
20. Menendez M, Castellsague J, Mirete M, Pros E, Feliubadalo L, et al. (2012) Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes. Breast Cancer Res Treat 132: 979-92.
21. Thomassen M, Blanco A, Montagna M, Hansen TV, Pedersen IS, et al. (2012) Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members. Breast Cancer Res Treat 132: 1009-23.
22. Houdayer C, Caux-Moncoutier V, Krieger S, Barrois M, Bonnet F, et al. (2012) Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants. Hum Mutat 33: 1228-38.
23. Spurdle AB, Couch FJ, Hogervorst FB, Radice P, Sinilnikova OM, (2008) Prediction and assessment of splicing alterations: implications for clinical testing. Hum Mutat 29: 1304-13.
24. Sharp A, Pichert G, Lucassen A, Eccles D, (2004) RNA analysis reveals splicing mutations and loss of expression defects in MLH1 and BRCA1. Hum Mutat 24: 272.
25. Walker LC, Whiley PJ, Couch FJ, Farrugia DJ, Healey S, et al. (2010) Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity. Hum Mutat 31: E1484-E1505.
26. Brandao RD, van RK, Tserpelis D, Garcia EG, Blok MJ, (2011) Characterisation of unclassified variants in the BRCA1/2 genes with a putative effect on splicing. Breast Cancer Res Treat 129: 971-82.
27. Mucaki EJ, Ainsworth P, Rogan PK, (2011) Comprehensive prediction of mRNA splicing effects of BRCA1 and BRCA2 variants. Hum Mutat 32: 735-42.
28. Manoukian S, Peissel B, Pensotti V, Barile M, Cortesi L, et al. (2007) Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families. Eur J Cancer 43: 601-6.
29. Cartegni L, Chew SL, Krainer AR, (2002) Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 3: 285-98.
30. Kaelin WG Jr, Pallas DC, DeCaprio JA, Kaye FJ, Livingston DM, (1991) Identification of cellular proteins that can interact specifically with the T/E1A-binding region of the retinoblastoma gene product. Cell 64: 521-32.
31. Houdayer C, (2011) In silico prediction of splice-affecting nucleotide variants. Methods Mol Biol 760: 269-81.
32. Shapiro MB, Senapathy P, (1987) RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. Nucleic Acids Res 15: 7155-74.
33. Yeo G, Burge CB, (2004) Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J Comput Biol 11: 377-94.
34. Reese MG, Eeckman FH, Kulp D, Haussler D, (1997) Improved splice site detection in Genie. J Comput Biol 4: 311-23.
35. Pertea M, Lin X, Salzberg SL, (2001) GeneSplicer: a new computational method for splice site prediction. Nucleic Acids Res 29: 1185-90.
36. Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, et al. (2009) Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 37: e67.
37. Brunak S, Engelbrecht J, Knudsen S, (1991) Prediction of human mRNA donor and acceptor sites from the DNA sequence. J Mol Biol 220: 49-65.
38. Hebsgaard SM, Korning PG, Tolstrup N, Engelbrecht J, Rouze P, et al. (1996) Splice site prediction in Arabidopsis thaliana pre-mRNA by combining local and global sequence information. Nucleic Acids Res 24: 3439-52.
39. Rogozin IB, Milanesi L, (1997) Analysis of donor splice sites in different eukaryotic organisms. J Mol Evol 45: 50-9.
40. Brendel V, Xing L, Zhu W, (2004) Gene structure prediction from consensus spliced alignment of multiple ESTs matching the same genomic locus. Bioinformatics 20: 1157-69.
41. Nalla VK, Rogan PK, (2005) Automated splicing mutation analysis by information theory. Hum Mutat 25: 334-42.
42. Schneider TD, (1997) Sequence walkers: a graphical method to display how binding proteins interact with DNA or RNA sequences. Nucleic Acids Res 25: 4408-15.
43. Machackova E, Foretova L, Lukesova M, Vasickova P, Navratilova M, et al. (2008) Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer. BMC Cancer 20 8: 140.
44. Colombo M, Ripamonti CB, Pensotti V, Foglia C, Peissel B, et al. (2009) An unusual BRCA2 allele carrying two splice site mutations. Ann Oncol 20: 1143-4.
45. Pensabene M, Spagnoletti I, Capuano I, Condello C, Pepe S, et al. (2009) Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling. Ann Oncol 20: 874-8.
46. Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, et al. (1994) Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 8: 399-404.
47. Ozcelik H, Nedelcu R, Chan VW, Shi XH, Murphy J, et al. (1999) Mutation in the coding region of the BRCA1 gene leads to aberrant splicing of the transcript. Hum Mutat 14: 540-1.
48. Peelen T, van van VM, Bosch A, Bignell G, Vasen HF, et al. (2000) Screening for BRCA2 mutations in 81 Dutch breast-ovarian cancer families. Br J Cancer 82: 151-6.
49. Yang Y, Swaminathan S, Martin BK, Sharan SK, (2003) Aberrant splicing induced by missense mutations in BRCA1: clues from a humanized mouse model. Hum Mol Genet 12: 2121-31.
50. Zhang L, Chen L, Bacares R, Ruggeri JM, Somar J, et al. (2011) BRCA1 R71K missense mutation contributes to cancer predisposition by increasing alternative transcript levels. Breast Cancer Res Treat 130: 1051-6.
51. Yang H, Jeffrey PD, Miller J, Kinnucan E, Sun Y, et al. (2002) BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science 297: 1837-48.
52. Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, et al. (2008) Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 29: 1282-91.
53. Zhang L, Bacares R, Boyar S, Hudis C, Nafa K, et al. (2009) cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation. Mutat Res 663: 84-9.
54. Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, et al. (2006) Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 43: 295-305.
55. Karchin R, Monteiro AN, Tavtigian SV, Carvalho MA, Sali A, (2007) Functional impact of missense variants in BRCA1 predicted by supervised learning. PLoS Comput Biol 3: e26.
56. Lee MS, Green R, Marsillac SM, Coquelle N, Williams RS, et al. (2010) Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays. Cancer Res 70: 4880-90.
57. Karchin R, Agarwal M, Sali A, Couch F, Beattie MS (2008) Classifying Variants of Undetermined Significance in BRCA2 with protein likelihood ratios. Cancer Inform 6: 203-16. Epub 2008 Apr 18.
58. Li L, Biswas K, Habib LA, Kuznetsov SG, Hamel N, et al. (2009) Functional redundancy of exon 12 of BRCA2 revealed by a comprehensive analysis of the c.6853A>G (p.I2285V) variant. Hum Mutat 30: 1543-50.
59. Spurdle AB, Healey S, Devereau A, Hogervorst FB, Monteiro AN, et al. (2012) ENIGMA-evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum Mutat 33: 2-7.